Research programme: neurodegenerative disease therapeutics - Vybion

Drug Profile

Research programme: neurodegenerative disease therapeutics - Vybion

Alternative Names: INT 41

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Vybion
  • Class Antibodies; Gene therapies
  • Mechanism of Action HD protein inhibitors; Protein folding modulators; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Huntington's disease
  • Research Alzheimer's disease; Spinocerebellar degeneration

Most Recent Events

  • 30 Jan 2017 Vybion receives Track I status for its patent application for INT 41 gene therapy in USA
  • 03 Nov 2015 Early research in Alzheimer's disease in USA (Parenteral) before November 2015
  • 03 Sep 2013 Early research in Spinocerebellar degeneration in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top